Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Mochi and Remedy Meds have emerged as telehealth platforms designed to lower barriers to GLP-1 access. Both operate virtual-first models connecting patients with clinicians and medications, yet they employ distinct sourcing, pricing, and delivery strategies. Understanding how these platforms work helps contextualize the broader GLP-1 landscape, where patients increasingly seek convenience alongside clinical confidence.
The choice between telemedicine platforms, branded medications, and compounded options involves more than convenience—it touches on medication sourcing, provider oversight, and whether personalized clinical insight aligns with treatment goals. PlexusDx takes a precision-wellness approach by pairing compounded GLP-1 medications from licensed 503A pharmacies with optional genetic pathway assessment to support more informed conversations with healthcare providers.
How Mochi and Remedy Meds Differ in GLP-1 Delivery
Mochi operates as a direct-to-consumer telehealth platform specializing in weight-loss and metabolic medications. Patients complete a virtual consultation, receive a provider assessment, and obtain prescriptions delivered via pharmacy partners. Mochi emphasizes accessibility and affordability, often marketing lower price points than branded alternatives.
Remedy Meds positions itself similarly—a telehealth-first service connecting patients with licensed prescribers and medication fulfillment. Remedy Meds may offer branded or generic GLP-1 options depending on availability and regional regulations. Both platforms reduce appointment friction and shipping delays, appealing to patients who prioritize convenience.
Neither Mochi nor Remedy Meds manufactures medications themselves. They facilitate prescription writing and outsource fulfillment to partner pharmacies. This model differs fundamentally from in-house compounding operations, which may offer different formulation options, dosing flexibility, and pricing structures.
Platform Model Comparison: Key Operational Differences
Mochi, Remedy Meds, and alternative channels like PlexusDx operate under different regulatory and clinical frameworks. The following comparison highlights how sourcing, provider oversight, and pricing align with each model's approach to GLP-1 access.
| Factor |
Mochi |
Remedy Meds |
PlexusDx Model |
| Medication Source |
Partner pharmacies; branded or generic |
Partner pharmacies; variable availability |
Licensed 503A compounding pharmacies only |
| Provider Model |
Virtual prescriber consultation; telehealth-based |
Virtual prescriber consultation; telehealth-based |
Patient works with qualified healthcare provider; optional genetic assessment |
| Pricing Transparency |
Often advertised low cost; subscription optional |
Competitive pricing; membership possible |
Fixed pricing per formulation; no hidden tiers |
| Personalization Options |
Standard dosing protocols |
Standard dosing protocols |
Compounded dose flexibility; optional Precision Peptide Genetic Test |
| Clinical Oversight |
Licensed prescriber review; limited ongoing assessment |
Licensed prescriber review; limited ongoing assessment |
Healthcare provider-directed; genetic pathway insight optional |
Clinical Evidence and GLP-1 Sourcing Considerations
GLP-1 medications—whether semaglutide, tirzepatide, or emerging compounds—have demonstrated clinical efficacy in randomized trials (STEP trials for semaglutide; SURMOUNT trials for tirzepatide). Efficacy data applies broadly across formulations, but patient-specific outcomes depend on metabolic factors, medication adherence, and provider oversight.
Medication sourcing matters clinically. Branded medications are FDA-approved and manufactured under strict pharmaceutical standards. Compounded medications prepared by licensed 503A pharmacies follow USP standards but are not FDA-approved products. Telemedicine platforms like Mochi and Remedy Meds typically source branded or generic versions, while PlexusDx exclusively partners with 503A compounding pharmacies for semaglutide, tirzepatide, and specialty formulations.
The sourcing choice does not determine clinical efficacy alone—provider oversight, adherence support, and dose optimization matter equally. Patients should understand whether their chosen platform offers ongoing clinical assessment versus transactional prescription fulfillment.
Genetic Factors and Personalized GLP-1 Response
Emerging research suggests genetic variation in GLP-1 receptor pathways, GIPR signaling, and metabolic genes may influence individual GLP-1 response patterns. Variants like GLP1R rs6923761 and FTO rs9939609 appear in some patients and may provide clinical context when interpreted by a qualified healthcare provider, though genetic testing does not predict exact medication response.
PlexusDx offers the Precision Peptide Genetic Test as an optional add-on to assess predispositions in peptide-pathway genes. This test may help provide context for conversations about why certain patients respond differently to GLP-1 therapy, supporting more informed clinical decision-making. The test is not a diagnostic tool or guaranteed predictor—it reveals genetic predispositions that can be integrated into a comprehensive clinical assessment.
Mochi and Remedy Meds do not currently offer genetic pathway testing. Their clinical model relies on standard prescriber evaluation and protocol-based dosing. For patients interested in whether genetic context might inform their GLP-1 response, this represents a meaningful difference in the available clinical tools.
Safety, Eligibility, and Provider Oversight
All GLP-1 services—telemedicine platforms included—require basic medical screening. Patients with personal or family history of thyroid cancer, multiple endocrine neoplasia, pancreatitis, or severe kidney disease should not use GLP-1 medications. Mochi and Remedy Meds conduct this screening via their virtual intake process, as do qualified providers working with PlexusDx patients.
Ongoing monitoring differs by platform. Telemedicine services may offer scheduled check-ins; PlexusDx encourages patients to maintain relationships with their primary healthcare provider for ongoing assessment, labs, and dose optimization. Compounded medications require the same clinical vigilance as branded options, and no platform should serve as a substitute for regular medical oversight.
Choosing between these platforms ultimately depends on personal priorities: whether you value telemedicine convenience (Mochi, Remedy Meds), compounded flexibility and sourcing transparency (PlexusDx), or genetic pathway context for clinical conversations. All require commitment to provider guidance and adherence protocols for safe, effective outcomes.
How PlexusDx Supports a More Personalized Approach
PlexusDx's genetic pathway approach differs from standard telemedicine screening. Rather than single-protocol dosing, PlexusDx integrates optional Precision Peptide Genetic Testing to help contextualize individual variation in GLP-1-pathway genes. This may support more tailored clinical conversations about why certain patients experience different response patterns, though genetic predisposition does not guarantee specific outcomes.
The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes that relate to peptide-pathway function. When interpreted by a qualified healthcare provider, this information can contribute to more informed medication selection and dosing discussions. PlexusDx emphasizes that this test reveals predispositions in genetic pathways—not exact medication response—and should always be discussed within a comprehensive clinical evaluation.
For patients comparing telehealth options, PlexusDx offers an alternative pathway: work with a qualified healthcare provider, consider whether genetic pathway insight might inform your clinical conversation, and access compounded GLP-1 medications from licensed 503A pharmacies. This model prioritizes provider relationship, medication transparency, and personalization tools over transactional convenience alone.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is Mochi, and how does it compare to Remedy Meds?
Mochi is a telehealth weight-loss platform connecting patients with virtual prescribers and partner pharmacies. Remedy Meds operates similarly—both offer convenient GLP-1 access without in-person visits. They differ in pharmacy partnerships and specific medication availability.
Do Mochi and Remedy Meds source compounded or branded GLP-1 medications?
Both platforms typically source branded or generic medications from partner pharmacies rather than compounded formulations. PlexusDx exclusively partners with licensed 503A compounding pharmacies, offering compounded semaglutide and tirzepatide with potential dose flexibility and transparent sourcing.
How does PlexusDx pricing compare to Mochi and Remedy Meds?
PlexusDx compounded semaglutide costs $149 monthly; tirzepatide $249 monthly. Mochi and Remedy Meds advertise competitive rates, but hidden fees and membership models may apply. Direct comparison requires reviewing each platform's full-cost breakdown with your provider.
Is the Precision Peptide Genetic Test available through Mochi or Remedy Meds?
No. Mochi and Remedy Meds do not offer genetic pathway testing. PlexusDx provides the Precision Peptide Genetic Test ($99 add-on or $298 standalone) to assess predispositions in peptide-related genes, supporting more informed clinical conversations with your healthcare provider.
Should I choose a telemedicine platform or work with a healthcare provider for GLP-1 therapy?
Both approaches can be valid. Telemedicine platforms prioritize convenience; PlexusDx emphasizes provider relationship, medication sourcing transparency, and optional genetic context. The best choice depends on your preference for clinical oversight, medication sourcing, and personalization tools.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Direct Meds Review: Evaluating Online GLP-1 Safety and Personalization
Orderly Meds Zepbound: Telehealth Access and Compounded GLP-1 Alternatives